Abstract
Next-generation sequencing approaches promise to become the future standard for drug-susceptibility testing and epidemiological investigation in tuberculosis and for other high-priority bacterial pathogenshttp://ow.ly/kXsV30lLP78
Footnotes
Conflict of interest: A.M. Cabibbe has nothing to disclose.
Conflict of interest: T.M. Walker has nothing to disclose.
Conflict of interest: S. Niemann reports grants from the German Center for Infection Research and Leibniz Science Campus Evolung, during the conduct of the study.
Conflict of interest: D.M. Cirillo has nothing to disclose.
- ReceivedJune 20, 2018.
- AcceptedSeptember 2, 2018.
- Copyright ©ERS 2018